Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4206967 | 1.00 | RIPK1 (0.37) | RIPK1PKMGLRA1GRM5ALDH1A1 | |
| SCHEMBL4206939 | 0.91 | PTGER1 (0.39) | GLRA1PTGER1 | |
| SCHEMBL13573330 | 0.86 | RIPK1 (0.39) | RIPK1PKMKDM4EMAPK1HPGD | |
| SCHEMBL4197420 | 0.84 | SMN1; SMN2 (0.46) | PKMALDH1A1LMNA | |
| SCHEMBL4192871 | 0.83 | ALDH1A1 (0.40) | ALDH1A1KDM4EMAPK1NPSR1LMNA | |
| SCHEMBL4049868 | 0.83 | SMN1; SMN2 (0.41) | GRM5ALDH1A1TSHRMAPK1LMNA | |
| SCHEMBL4046964 | 0.82 | LMNA (0.39) | ALDH1A1TSHRNPSR1LMNAHPGD | |
| SCHEMBL4270118 | 0.82 | RAB9A (0.38) | PKMGLRA1GRM5ALDH1A1KDM4E | |
| SCHEMBL4198917 | 0.79 | RIPK1 (0.40) | RIPK1KDM4E | |
| SCHEMBL4200754 | 0.78 | LMNA (0.35) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312335-A1 | Hiv Integrase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-12-17 | — | — | US | disclosed |
| EP-1758585-A4 | HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7476666-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-20080015187-A1 | Hiv Integrase Inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-17 | — | — | US | disclosed |
| EP-1758585-A2 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005120516-A2 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312335-A1 | Hiv Integrase Inhibitors | RECQL, TYMP, POLR2H | RIPK1 1256/4885PKM 1384/4885GLRA1 3181/4885 |
| US-20080015187-A1 | Hiv Integrase Inhibitors | REV1, ZC3HAV1, PNP | RIPK1 1583/4885PKM 1813/4885GLRA1 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.